Observation and Evaluation of the Efficacy and Safety of Adalimumab Combined with Chemotherapy Followed by Radiotherapy or Radiotherapy Alone as First-Line Treatment for Limited-Stage Small Cell Lung Cancer
Age: 18-75 years old, male or female;
Patients with pathologically confirmed localized small cell lung cancer (as defined by the Veterans Administration Lung Study Group, VALG staging);
No anticipated need for tumor resection during the study period (including patients unsuitable for surgery or unwilling to undergo surgery);
No prior treatment for localized small cell lung cancer;
Mixed SCLC and extensive-stage SCLC;
History of other malignancies within the past 5 years or concurrent malignancies, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, or superficial or non-invasive bladder cancer;
History of uncontrollable psychiatric disorders or severe intellectual or cognitive impairment;
Active, known, or suspected autoimmune disease; however, subjects with hypothyroidism requiring only hormone replacement therapy or skin conditions not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia) are eligible;